PXT3003

DRUG2 trials

Sponsors

Pharnext S.C.A., Tasly GeneNet Pharmaceuticals Co., Ltd

Conditions

Charcot-Marie-Tooth Disease, Type IACharcot-Marie-Tooth Type 1A

Phase 3

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Active, not recruitingNCT03023540

Pharnext S.C.A.Charcot-Marie-Tooth Disease, Type IA

Start: 2017-03-07End: 2024-12-31Updated: 2024-02-20

A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

CompletedNCT05092841

Tasly GeneNet Pharmaceuticals Co., LtdCharcot-Marie-Tooth Type 1A

Start: 2021-09-28End: 2024-03-18Updated: 2025-01-09